Cowen and Company’s Denali Therapeutics DNLI Stock Holding History

Cowen and Company’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-25,000	Closed	-$65K	–	103
2024 Q3	$65K	Buy	+25,000	New	+$620K	﹤0.01%	320

Other funds holding DNLI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Cowen and Company's DNLI Position: Q4 2024 in Review

Cowen and Company sold out of Denali Therapeutics (DNLI) in Q4 2024, closing a stake of 15,800 shares — an estimated $460K sold.

Cowen and Company first reported a position in DNLI in Q3 2024 and held it in 1 quarter. The position peaked at $460K in Q3 2024. 223 funds tracked by Wall St. Rank hold DNLI as of Q4 2024.

Cowen and Company reported no remaining Denali Therapeutics position as of Q4 2024 after selling out during the quarter.
Cowen and Company sold 15,800 Denali Therapeutics shares in Q4 2024, an estimated $460K.
Cowen and Company first reported a position in Denali Therapeutics in Q3 2024 and held it in 1 quarter.
Cowen and Company's Denali Therapeutics position peaked at $460K in Q3 2024.
223 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2024.

Based on Cowen and Company's 13F filing for Q4 2024.